---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-25-000039"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:51:02.766329+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "low"
source: SEC EDGAR
---

# Halozyme issues position statement on CMS final IPAY 2028 Medicare negotiation guidance

## Summary
- Statement includes long-term projections of U.S. Medicare Part B spend as % of total ENHANZE partner product SC sales.
- No specific financial projections or quantitative details were disclosed in the 8-K or attached exhibit.
- The exhibit text provided is only a title; substantive content must be accessed on the company's website.

## SEC filing metadata
- accession: 0001159036-25-000039
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000039/0001159036-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903625000039/halo-20251014.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-25-000039
- JSON: https://secwatch.observer/filing/0001159036-25-000039.json
- Plain text: https://secwatch.observer/filing/0001159036-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.